Molecular pathogenesis of bladder cancer

被引:88
作者
Knowles, Margaret A. [1 ]
机构
[1] St James Univ Hosp, Leeds Inst Mol Med, Canc Res UK Clin Ctr, Leeds LS9 7TF, W Yorkshire, England
关键词
bladder; molecular pathogenesis; genetics; pathways;
D O I
10.1007/s10147-008-0812-0
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Bladder tumors show widely differing histopathology and clinical behavior. This is reflected in the molecular genetic alterations they contain. Much information has accumulated on somatic genomic alterations in bladder tumors of all grades and stages and when this information is related to the common histopathological appearances, a model for the pathogenesis of two major groups of bladder tumors has emerged. This review summarizes the genetic alterations that have been reported in bladder cancer and relates these to the current two-pathway model for tumor development. The molecular pathogenesis of high-grade noninvasive papillary tumors and of T1 tumors is not yet clear and possibilities are discussed.
引用
收藏
页码:287 / 297
页数:11
相关论文
共 132 条
[1]   Alteration of the PATCHED locus in superficial bladder cancer [J].
Aboulkassim, TO ;
LaRue, H ;
Lemieux, P ;
Rousseau, F ;
Fradet, Y .
ONCOGENE, 2003, 22 (19) :2967-2971
[2]   Human bladder tumors with 2-hit mutations of the tumor suppressor gene TSC1 and decreased expression of p27 [J].
Adachi, H ;
Igawa, M ;
Shiina, H ;
Urakami, S ;
Shigeno, K ;
Hino, O .
JOURNAL OF UROLOGY, 2003, 170 (02) :601-604
[3]   Infrequent mutation of TRAIL receptor 2 (TRAIL-R2/DR5) in transitional cell carcinoma of the bladder with 8p21 loss of heterozygosity [J].
Adams, J ;
Cuthbert-Heavens, D ;
Bass, S ;
Knowles, MA .
CANCER LETTERS, 2005, 220 (02) :137-144
[4]  
Adams J, 2005, CANCER RES, V65, P66
[5]   Somatic mutation of PTEN in bladder carcinoma [J].
Aveyard, JS ;
Skilleter, A ;
Habuchi, T ;
Knowles, MA .
BRITISH JOURNAL OF CANCER, 1999, 80 (5-6) :904-908
[6]  
Bakkar AA, 2003, CANCER RES, V63, P8108
[7]   Level of retinoblastoma protein expression correlates with p16 (MTS-1/INK4A/CDKN2) status in bladder cancer [J].
Benedict, WF ;
Lerner, SP ;
Zhou, J ;
Shen, XH ;
Tokunaga, H ;
Czerniak, B .
ONCOGENE, 1999, 18 (05) :1197-1203
[8]  
Berggren P, 2003, CLIN CANCER RES, V9, P235
[9]   Frequent FGFR3 mutations in papillary non-invasive bladder (pTa) tumors [J].
Billerey, C ;
Chopin, D ;
Aubriot-Lorton, MH ;
Ricol, D ;
de Medina, SGD ;
Van Rhijn, B ;
Bralet, MP ;
Lefrere-Belda, MA ;
Lahaye, JB ;
Abbou, CC ;
Bonaventure, J ;
Zafrani, ES ;
van der Kwast, T ;
Thiery, JP ;
Radvanyi, F .
AMERICAN JOURNAL OF PATHOLOGY, 2001, 158 (06) :1955-1959
[10]   Bladder cancer stage and outcome by array-based comparative genomic hybridization [J].
Blaveri, E ;
Brewer, JL ;
Roydasgupta, R ;
Fridlyand, J ;
DeVries, S ;
Koppie, T ;
Pejavar, S ;
Mehta, K ;
Carroll, P ;
Simko, JP ;
Waldman, FM .
CLINICAL CANCER RESEARCH, 2005, 11 (19) :7012-7022